MYELODYSPLASTIC SYNDROMES

Feature

MDS, AML a Risk With PARP Inhibitors in <em>BRCA</em> Mutation Carriers

What is the concern behind PARP inhibitors and leukemia?

Latest News

Proposed Updates to Treatment Response Criteria for Patients With Myelodysplastic Syndromes

By

The current set of standardized treatment response criteria was most recently revised in 2006 and had many shortcomings when applied to clinical trials.

Eltrombopag Plus Azacitidine May Lead to Worse Survival in Patients With Myelodysplastic Syndrome

By

Up to 65% of patients with myelodysplastic syndrome experience comorbid thrombocytopenia.

Immunosuppressive Therapy May Predict Improved Survival in Myelodysplastic Syndromes

By

Immunosuppressive therapy is used sparingly due to the operational challenges in administration and prediction of patient benefit.

Mutations After Transplant in Myelodysplastic Syndrome May Correlate With Progressed Disease

By

The presence of persistent disease-related mutations 30 days after ASCT for myelodysplastic syndrome was associated with higher risk of disease progression.

Myeloablative Conditioning Effective in AML Secondary to MDS/MPN Prior to Allogeneic HCT

By James Nam, PharmD

In the EBMT ALWP study, researchers sought to determine the efficacy of myeloablative conditioning to reduce the risk for post allogeneic HCT in patients with sAML without significantly increasing non-relapse mortality.

Lurbinectedin a Possible Option for Acute Myeloid Leukemia, Myelodysplastic Syndrome

By James Nam, PharmD

A phase 1 dose-finding study determined which of 2 lurbinectedin dosing schedules had greater effectiveness and fewer AEs in patients with relapsed/refractory MDS or AML.

Alcohol May Reduce Risk of Myelodysplastic Syndrome

By James Nam, PharmD

Smoking may slightly increase the risk for myelodysplastic syndromes, but alcohol consumption may be significantly protective against MDS.

DSP-7888 Granted Orphan Drug Status for Myelodysplastic Syndrome

By James Nam, PharmD

The US Food and Drug Administration granted orphan drug designation to DSP-7888 for myelodysplastic syndrome.

Reduced-intensity Conditioning for Stem Cell Transplantation Effective in MDS

By Andrea S. Blevins Primeau, PhD, MBA

The results of this study suggest that RIC may be an alternative to MAC, particularly for patients of low cytogenetic risk.

Complex Karyotype, TP53 Mutations Associated With HCT Outcomes in Myelodysplasia

By Andrea S. Blevins Primeau, PhD, MBA

Based on the results of this study, an alternative to HCT should be considered for patients with CK and mutations in TP53 or the RAS pathway.

Eltrombopag for Lower-risk MDS With Severe Thrombocytopenia

By Jason Hoffman, PharmD, RPh

Eltrombopag was well-tolerated, significantly raised platelet counts, and reduced bleeding events among patients with MDS and severe thrombocytopenia.

SIGN UP FOR FREE E-NEWSLETTERS